<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04053140</url>
  </required_header>
  <id_info>
    <org_study_id>251161</org_study_id>
    <nct_id>NCT04053140</nct_id>
  </id_info>
  <brief_title>Closed-loop Control of Penicillin Delivery</brief_title>
  <acronym>CLCPD</acronym>
  <official_title>Closed-loop Control of Penicillin Delivery Integrating Electrochemical Biosensor Technology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an in-house feasibility study of penicillin biosensor technology linked with&#xD;
      closed-loop control for the automated delivery of penicillin antibiotics.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Outline of the study:&#xD;
&#xD;
      This study will take place at the Imperial Clinical Research Facility (ICRF). Twenty healthy&#xD;
      volunteers will be recruited to take part in three visits to the ICRF. These will each last&#xD;
      8-12 hours. During these visits participants will receive penicillin via infusion following:&#xD;
&#xD;
      (i) Routine (intermittent or continuous) dosing protocols. (ii) Intermittent dosing directed&#xD;
      by a closed-loop control system. (iii) Continuous dosing directed by a closed-loop control&#xD;
      system. Participants will have up to 15 blood samples and tissue microdialysis performed. A&#xD;
      biosensor will also be used to provide real-time antibiotic concentration data. This will be&#xD;
      used to drive the closed-loop control system. Outcome measures will be PK-PD target&#xD;
      attainment between visits. This target will be 50% time &gt; MIC and 100% time &gt; MIC.&#xD;
&#xD;
      Participant identification:&#xD;
&#xD;
      Healthy volunteers will be recruited from a healthy volunteer database held within Imperial&#xD;
      College London and via identification of participants within the College. An initial&#xD;
      advertisement e-mail will be sent by the Healthy Volunteer Database Administrator and&#xD;
      individuals responding will then followed up by telephone or e-mail and invited to attend a&#xD;
      screening visit at the ICRF. They will be sent the participant information leaflet via email&#xD;
      in advance of this meeting to give them time to consider the information.&#xD;
&#xD;
      Study methodology:&#xD;
&#xD;
        -  Twenty healthy volunteers will be invited to participate in an exploratory study of the&#xD;
           biosensor device and closed-loop control systems.&#xD;
&#xD;
        -  Allergy status will be confirmed with the participant at each visit.&#xD;
&#xD;
        -  Study days will follow the same format. The only deviation will be the method of&#xD;
           penicillin delivery (this will either be by routine infusion, closed-loop intermittent&#xD;
           infusion, or closed-loop continuous infusion).&#xD;
&#xD;
        -  On the night before study visits, participants will be asked to refrain from drinking&#xD;
           alcohol. On the study day they will be invited to bring a laptop / tablet device for&#xD;
           their entertainment. Alternatively, one will be provided on the study day by the ICRF.&#xD;
&#xD;
        -  On arrival at the study center the participant will have a microneedle biosensor sited.&#xD;
&#xD;
        -  They will have two cannulae inserted, ideally one in each arm. One of these will be for&#xD;
           taking blood during the study. The other will be for penicillin delivery.&#xD;
&#xD;
        -  They will also have a microdialysis fibre inserted in the same arm as the microneedle&#xD;
           array.&#xD;
&#xD;
        -  A baseline blood sample will be taken (full blood count, renal function, liver function,&#xD;
           and C-reactive protein) on each visit.&#xD;
&#xD;
        -  The microneedle biosensor will be sited peripherally (on the non-dominant arm). These&#xD;
           sensors are connected to potentiostat devices that record data, which can then be&#xD;
           downloaded onto a computer for analysis.&#xD;
&#xD;
        -  The study will then commence at time = 0 when the first infusion of penicillin will be&#xD;
           given.&#xD;
&#xD;
        -  In total, the study will run for 3 benzylpenicillin dosing intervals (8-12 hours). For&#xD;
           intermittent, routine care benzylpenicillin doses will be given at time = 0, 4, and 8&#xD;
           hours. During closed-loop control visits the controller will be allowed to determine the&#xD;
           dosing interval / period. The controller will be limited to deliver a MAXIMUM dose&#xD;
           equivalent to 2.4g every 4-hours.&#xD;
&#xD;
        -  During the study interval the participant will undergo rich blood and microdialysis drug&#xD;
           concentration sampling. For blood sampling, up to 15 beta-lactam drug levels will be&#xD;
           taken during the study visit period. Each blood test will involve the collection of 5mLs&#xD;
           of blood (1 teaspoon). Microdialysis will be performed continuously for the study&#xD;
           period. The collection vial will be changed every 15-30 minutes during the study period.&#xD;
&#xD;
        -  In addition, a blood spot will be used from the blood samples taken as part of the PK&#xD;
           sampling to test point-of-care penicillin sensors at the time-points described below.&#xD;
&#xD;
        -  A visual analogue scale will be completed by the participant every hour to evaluate&#xD;
           their level of discomfort due to the microneedle sensor device. The device and site will&#xD;
           also be checked by researchers every hour.&#xD;
&#xD;
        -  Time points for the blood sampling are planned to initially be taken at pre, 6, 10, 15,&#xD;
           30, 60, 120, 180, 240, 246, 250, 300, 480, 486, 600 minutes. However, following initial&#xD;
           PK analysis a D-optimal design will be employed using Pmetrics and BestDose&#xD;
           pharmacokinetic software to determine the optimal time points for blood PK analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 5, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the biosensors ability to track benzylpenicillin concentrations compared to observations made by microdialysis and blood sampling.</measure>
    <time_frame>Up to 12 hours.</time_frame>
    <description>Bland-Altman plot to describe agreement between interstitial benzylpenicillin concentrations and microneedle data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare PK-PD target attainment between visits</measure>
    <time_frame>Up to 12 hours.</time_frame>
    <description>Compare time &gt; MIC between visits</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Routine intermittent slow bolus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed. Benzylpenicillin IV 1200mg administered every 4 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Closed-loop control of intermittent slow bolus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed. Benzylpenicillin IV administered in intermittent dosing schedule. Dosage to be determined by closed-loop algorithm. Limits set to 2400mg every 4 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Closed-loop control of continuous infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed. Benzylpenicillin IV administered in continuous dosing schedule. Dosage to be determined by closed-loop algorithm. Initial loading dose, and limits set to 600mg/hr.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Microneedle array</intervention_name>
    <description>The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed.</description>
    <arm_group_label>Routine intermittent slow bolus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Microneedle array and closed-loop control of penicillin delivery</intervention_name>
    <description>The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed. Microneedle data will be used to titrate benzylpenicillin dosage according to PK-PD target.</description>
    <arm_group_label>Closed-loop control of continuous infusion</arm_group_label>
    <arm_group_label>Closed-loop control of intermittent slow bolus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Penicillin G_1200mg</intervention_name>
    <description>Benzylpenicillin IV 1200mg administered every 4 hours.</description>
    <arm_group_label>Routine intermittent slow bolus</arm_group_label>
    <other_name>Benzylpenicillin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Penicillin G_2400mg</intervention_name>
    <description>Benzylpenicillin IV administered in intermittent dosing schedule. Dosage to be determined by closed-loop algorithm. Limits set to 2400mg every 4 hours.</description>
    <arm_group_label>Closed-loop control of intermittent slow bolus</arm_group_label>
    <other_name>Benzylpenicillin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Penicillin G_600mg/hr</intervention_name>
    <description>Benzylpenicillin IV administered in continuous dosing schedule. Dosage to be determined by closed-loop algorithm. Initial loading dose, and limits set to 600mg/hr.</description>
    <arm_group_label>Closed-loop control of continuous infusion</arm_group_label>
    <other_name>Benzylpenicillin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult &gt;18 years old.&#xD;
&#xD;
          -  Healthy adults, with no evidence of infection.&#xD;
&#xD;
          -  Previously received penicillin with no adverse effects.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt; 18 years old.&#xD;
&#xD;
          -  High risk of skin and soft tissue infection or local skin and soft tissue infection&#xD;
             near sensor site.&#xD;
&#xD;
          -  Hypersensitivity to adhesive strips or active dermatitis.&#xD;
&#xD;
          -  Penicillin hypersensitivity or previous adverse event whilst receiving penicillin.&#xD;
&#xD;
          -  Anaemia on screening bloods (defined as haemoglobin &lt;13 g/dL in males and &lt;12 g/dL in&#xD;
             females).&#xD;
&#xD;
          -  Renal impairment on screening bloods (defined as a Cockcroft-Gault creatinine&#xD;
             clearance &lt;60mL/min).&#xD;
&#xD;
          -  Liver impairment on screening bloods (defined as ALT, ALP or bilirubin 3x ULN).&#xD;
&#xD;
          -  Implantable electronic device in-situ if wearing a microneedle array device.&#xD;
&#xD;
          -  Pregnant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alison H Holmes, MD MPH MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Health Protection Research Unit in HCAI &amp; AMR</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richard C Wilson, MSc MPharm</last_name>
    <phone>+44(0)2033132732</phone>
    <email>richard.wilson@imperial.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julliet R Alibone</last_name>
    <phone>+44(0)2033132732</phone>
    <email>head.ops@imperial.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NIHR Imperial CRF</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NIHR Imperial CRF</last_name>
      <phone>+44(0)20 3313 8070</phone>
      <email>Imperial.CRF@nhs.net</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.gov/ct2/show/NCT03847610</url>
    <description>Minimally Invasive Sensing of Beta-lactam Antibiotics (MISBL)</description>
  </link>
  <reference>
    <citation>Gowers SAN, Freeman DME, Rawson TM, Rogers ML, Wilson RC, Holmes AH, Cass AE, O'Hare D. Development of a Minimally Invasive Microneedle-Based Sensor for Continuous Monitoring of Î²-Lactam Antibiotic Concentrations in Vivo. ACS Sens. 2019 Apr 26;4(4):1072-1080. doi: 10.1021/acssensors.9b00288. Epub 2019 Apr 17.</citation>
    <PMID>30950598</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 24, 2019</study_first_submitted>
  <study_first_submitted_qc>August 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2019</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Penicillin G</keyword>
  <keyword>Penicillins</keyword>
  <keyword>Proof of Concept Study</keyword>
  <keyword>Clinical Trial, Phase I</keyword>
  <keyword>Microneedle array</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Penicillins</mesh_term>
    <mesh_term>Penicillin G</mesh_term>
    <mesh_term>Penicillin G Benzathine</mesh_term>
    <mesh_term>Penicillin G Procaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

